- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced the appointment of Joy A. Thomas as vice president of corporate development. Ms. Thomas will be integral to BioSante implementing its corporate development strategies, including collaborations and licensing.
Ms. Thomas comes to BioSante after 13 years with Baxter Healthcare Corporation where she was most recently Senior Director, Global Strategy & Business Development for its Renal Division. Earlier she was Director, Strategic Marketing and Planning for its Medication Delivery Division. Ms. Thomas holds a Bachelor of Science degree in Finance and Russian from the University of Illinois, and a Master of Business Administration in International Business and Finance from the University of Chicago.
"We are very pleased to have Joy Thomas joining us at this exciting time for BioSante," said Stephen M. Simes, BioSante's president and chief executive officer. "Joy's experience and expertise will be invaluable in assessing BioSante's strategic alternatives in view of the excellent progress we have made, especially related to FDA clarity on the development of LibiGel® in the treatment of female sexual dysfunction. We remain dedicated to our objective of maximizing stockholder value and believe Joy will be integral to this endeavor."
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine.
For more information, please click here
BioSante Pharmaceuticals, Inc.
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Yale researchers’ technology turns wasted heat into power June 27th, 2016
FEI Launches Helios G4 DualBeam Series for Materials Science: The Helios G4 DualBeam Series features new capabilities to enable scientists and engineers to answer the most demanding and challenging scientific questions June 27th, 2016